Clinical trial
Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory…
NCT00227721 · Robert Morris, Other · Completed
Key facts
| NCT number | NCT00227721 |
|---|---|
| Title | Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer |
| Official title | Phase II Trial of Weekly Gemcitabine and Docetaxel Combination Therapy for Relapsed Ovarian or Peritoneal Cancer |
| Lead sponsor | Robert Morris, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Gemcitabine hydrochloride |
| Enrollment | 30 |
| Start date | Feb 1, 2004 |
| Primary completion | Jun 1, 2011 |
| Completion | Feb 1, 2017 |
| First posted | Sep 28, 2005 |
| Last update posted | Dec 2, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: